BioArctic AB today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed target in neurodegeneration. As part of the initial research collaboration, BioArctic will receive .USD 30 million in upfront payment.

BioArctic AB今天宣布公司已与诺华制药达成一项期权、合作和许可协议，涉及将BioArctic专有的BrainTransporter技术与神经退行性疾病中一个未公开靶点结合的潜在新疗法。作为初始研究合作的一部分，BioArctic将获得3000万美元预先付款。

Novartis will evaluate the data generated during the initial collaboration and decide whether to exercise their option to license any drug candidate generated. If Novartis exercises their option, BioArctic will be eligible to receive additional payments of up to USD 772 million

诺华将评估在初步合作期间生成的数据，并决定是否行使他们对任何产生的药物候选物的许可选择权。如果诺华行使该选择权，BioArctic将有资格获得额外的付款，最高可达7.72亿美元

. BioArctic will also be entitled to tiered mid-single digit royalties on future global product sales if the product reaches the market.

如果该产品成功上市，BioArctic还将有权获得未来全球产品销售的分级中个位数百分比的特许权使用费。

Under the initial research collaboration, BioArctic will generate a new drug candidate combining the BrainTransporter technology with a Novartis proprietary antibody. Should Novartis decide to exercise their option following the evaluation of the generated drug candidate, Novartis will assume full responsibility for the global development and commercialization of the drug candidate and related products..

根据初步研究合作协议，BioArctic将利用BrainTransporter技术与诺华的专利抗体结合，生成一种新的候选药物。如果诺华在评估生成的候选药物后决定行使选择权，诺华将全面负责该候选药物及其相关产品的全球开发和商业化。

'I'm excited by today's announcement. Novartis shares our passion for science and helping patients with severe neurological disorders. With yet another BrainTransporter agreement it is becoming evident that this versatile platform has huge potential to improve many different projects, internally as well as externally generated, and could support companies across the field in their pursuit of helping people with brain disorders,' said .

“我对今天的公告感到兴奋。诺华公司与我们一样，对科学充满热情，并且致力于帮助患有严重神经系统疾病的患者。随着又一项BrainTransporter协议的达成，这一多功能平台的巨大潜力正变得显而易见，它能够改进许多不同的项目，无论是内部还是外部生成的项目，并且可以支持整个领域的公司，帮助他们为脑部疾病患者提供支持，”他表示。

Gunilla Osswald, CEO at BioArctic.

Gunilla Osswald，BioArctic首席执行官。

'At Novartis, we are deeply committed to advancing science to help discover treatments for devastating nervous system disorders,' said Sophie Parmentier Batteur, Head of Neurodegeneration Research at Novartis. 'Collaborating with BioArctic allows us to explore the exciting potential of the BrainTransporter technology to promote brain uptake and optimize systemic delivery of novel therapeutic agents by leveraging the biology of the blood-brain barrier.

“在诺华，我们深致力于推进科学的发展，以帮助发现治疗毁灭性神经系统疾病的方法，”诺华神经退行性疾病研究主管 Sophie Parmentier Batteur 表示。“与 BioArctic 合作使我们能够探索 BrainTransporter 技术令人兴奋的潜力，通过利用血脑屏障的生物学特性来促进大脑吸收并优化新型治疗药物的系统递送。”

Our focus is to pioneer innovative therapies that improve treatment outcomes by impacting disease progression, to provide meaningful therapies for patients with severe neurological conditions.'.

我们的重点是开创能够通过影响疾病进展来改善治疗效果的创新疗法，为患有严重神经系统疾病的患者提供有意义的治疗方案。

This agreement is the third

本协议为第三项协议

collaboration BioArctic has entered into with partners using the BrainTransporter technology. BioArctic retains all rights for use of the BrainTransporter platform outside of the scope of these three agreements. The BrainTransporter platform can be used in a number of different therapy areas for delivery of biologics and other modalities, giving BioArctic many potential future partnering opportunities. .

BioArctic与使用BrainTransporter技术的合作伙伴达成的合作。BioArctic保留了这三项协议范围之外使用BrainTransporter平台的所有权利。BrainTransporter平台可用于多个不同的治疗领域，用于递送生物制品和其他方式，为BioArctic提供了许多潜在的未来合作机会。

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

本发布稿讨论了正在开发中的药物的试验性用途，不旨在传达有关有效性和安全性的结论。不能保证这种试验性药物会成功完成临床开发或获得卫生当局的批准。

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on

此信息是BioArctic AB（publ）根据欧盟市场滥用法规有义务披露的信息。该信息通过以下联系人向公众发布于

About the BrainTransporter™ technology

关于BrainTransporter™技术

BioArctic's BrainTransporter technology is a technology for facilitating the passage of biological drugs as for example antibodies into the brain using the transferrin receptor (TfR). Active transport of biotherapeutics across the blood brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience.

BioArctic的BrainTransporter技术是一种利用转铁蛋白受体（TfR）促进生物药物（如抗体）进入大脑的技术。通过血脑屏障主动运输生物治疗药物可以实现更广泛的大脑分布，从而提高疗效、改善安全性并方便剂量使用。

The technology is being applied to several in-house drug projects, and could become part of future collaborations with other pharma companies..

该技术正在被应用于几个内部药物项目，并可能成为未来与其他制药公司合作的一部分。

About BioArctic AB

关于BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi

BioArctic AB（publ）是一家瑞典研究型生物制药公司，专注于开发能够延缓或阻止神经退行性疾病进展的创新疗法。该公司发明了Leqembi。

(lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease.

（lecanemab）——全球首款被证明可以减缓疾病进展并减轻早期阿尔茨海默病认知障碍的药物。Leqembi由BioArctic的合作伙伴卫材共同开发，卫材负责全球的监管互动和商业化。除了Leqembi，BioArctic还拥有针对帕金森病和肌萎缩侧索硬化症（ALS）的抗体研究组合，以及更多针对阿尔茨海默病的项目。

Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit .

几个项目利用了该公司的专有BrainTransporter™技术，这项技术有可能主动将抗体转运穿过血脑屏障，从而提高治疗效果。BioArctic的B股（BIOA B）在纳斯达克斯德哥尔摩大盘股上市。欲了解更多信息，请访问。